Nuclear medicine imaging is growing faster than any other imaging modality — driven by the theranostics revolution that is creating clinical demand for high-quality PET/CT imaging of theranostic targets, new radiopharmaceuticals for oncology and neurology, and total-body PET systems enabling new research and clinical applications. GE HealthCare's pharmaceutical diagnostics segment at $2.9 billion growing 15.6% is the strongest commercial evidence of the nuclear medicine growth opportunity. Siemens Healthineers, Philips, and Canon Medical compete in PET/CT and SPECT/CT equipment.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Nuclear Medicine Market Overview
• PET
• CT Market Dynamics
• SPECT
• CT Technology and Market
• Theranostics Equipment Requirements
• Radiopharmaceutical Market
• Total-Body PET
• Competitive Landscape
Table of Contents
1. Executive Summary
2. Market Overview
3. PET/CT Systems
4. SPECT/CT Systems
5. Total-Body PET
6. Radiopharmaceuticals
7. Theranostics Commercial Landscape
8. Digital and AI Integration
9. Competitive Landscape
10. Regional Market Analysis
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Market Size and Growth 2025
Table 2. Segment Breakdown 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Market Share 2025
Table 4. M&A and Innovation Activity 2023-2025
Table 5. Regional Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Bayer
Cardinal Health
GE HealthCare
Lantheus
Novartis AAA
POINT Biopharma
Siemens Healthineers
